DLBCL

Conference Coverage

CAR T for all R/R DLBCL patients: The jury is still out

Author:

Sharon Worcester

Publish date: October 28, 2020

The CAR T data are encouraging, but high-dose therapy and stem cell rescue may be just as good in chemosensitive...

• Read More

News

Seven things to know about new lymphoma drug tafasitamab

Author:

Kate O’Rourke

Publish date: October 9, 2020

“This is an option for patients who are not candidates for potentially curative approaches, including ASCT and...

• Read More

Conference Coverage

Survey quantifies COVID-19’s impact on oncology

Author:

Walter Alexander

Publish date: September 20, 2020

Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.

• Read More

News

FDA approves new drug for diffuse large B-cell lymphoma

Author:

Zosia Chustecka

Publish date: August 4, 2020

The humanized CD19-targeting monoclonal antibody mediates B-cell lysis through apoptosis and an immune effector...

• Read More

News

HSCT or systemic treatment should be offered to HIV+ patients with lymphoma

Author:

Mark S. Lesney, PhD

Publish date: July 16, 2020

Patients with lymphoma and HIV infection benefit from systemic or stem cell therapy, but with worse outcomes...

• Read More

News

FDA approves selinexor for relapsed/refractory DLBCL

Author:

Mark S. Lesney, PhD

Publish date: June 23, 2020

Selinexor is approved for adults with relapsed/refractory DLBCL, including DLBCL arising from follicular...

• Read More

Conference Coverage

Adding avadomide shows promise for newly diagnosed DLBCL

Author:

Will Pass

Publish date: June 5, 2020

For patients with newly diagnosed, high-risk diffuse large B-cell lymphoma, adding avadomide to standard therapy...

• Read More

News

Race and location appear to play a role in the incidence of CLL and DLBCL

Author:

Mark S. Lesney

Publish date: May 20, 2020

Urban non Hispanic blacks and Hispanics have an increased incidence of CLL, DLBCL, respectively vs. rural....

• Read More

News

DLBCL patients at academic centers had significantly better survival

Author:

Mark S. Lesney

Publish date: May 11, 2020

Researchers suggested that academic centers might provide increased access to clinical trials, improved physician expertise, improved treatment...

• Read More

News

Safer CAR uses modified NK cells for advanced CLL, NHL

Author:

Neil Osterweil

Publish date: February 19, 2020

Allogeneic CAR-NK cells can be delivered in adoptive transfer without the serious cytokine release syndrome and...

• Read More

Pages

• « first
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• last »